OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
18/06/2026
Voltar para busca
Dado oficial do USPTO
RHYGAZE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
24
Atualização mais recente
19/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
08/11/2024
Data de registro
03/03/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/03/2026
Última transação
19/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
Basel, CH
Examinador
HUDSON, TAMARA BREE
Unidade examinadora
L40
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
RhyGaze AG
Representantes
James R Menker Holley & Menker, PA
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medical preparationsophthalmologic preparations; biological medical and pharmaceutical preparations for treating ophthalmologic conditionsailmentsdiseases and disorders; Pharmaceutical and medical preparations for treating eye diseases; biological medical and pharmaceutical preparations for treating eye diseases; pharmaceutical and biological preparations for use in cell cultures for medical purposesnucleic acidsprotein arraysprotein conjugatessynthetic peptidesattenuated virusesviral vectors and viral constructions; biological tissue cultures for medical use; biological tissue cultures intended for medical use in the diagnosisprevention and treatment of diseasesin particular eye diseases; biological tissue cultures intended for medical use in gene therapy treatments; pharmaceutical preparations for use in genetic-based therapiesgene therapy preparationsgene-editing preparationsgenome-editing preparationspreparations incorporating CRISPR-based therapeutic agents for the treatment of eye diseases and other medical conditions; biological preparations comprising genetically modified cellsmodified nucleic acidsviral and non-viral vectors for use in gene therapy and genome-editing medical treatments; all of the foregoing excluding preparations or other goods for the treatment of cancer and oncological diseases and disorders
Classe 42
Scientific and technological servicesresearch and design services relating to gene therapygenetic-based therapiesgenome-editing technologiesCRISPR technologiesmolecular biologybiotechnologypharmacy and medicine; quality control for others and authentication of data in the field of medical records using blockchain technology; design and development of computers and software; research and development services in the fields of molecular biologybiotechnologypharmacy and medicine; research and development services in the fields of molecular biologybiotechnologypharmacy and medicinein particular in the field of eye diseases; research and development services in the field of medical diagnosticsprophylaxis and therapyin particular gene therapy; research servicesscientific examination and research of compounds and components intended for therapeutic or diagnostic usein particular intended for use in relation to eye diseases; research services in the field of gene therapy; research and development in the fields of genome editingCRISPR-based technologiesgenetic-engineering tools for medical and therapeutic use; scientific research for developing protocolsfor technical planningfor providing advice in the fields of molecular biologybiotechnology and pharmacyin particular intended for use in the field of ocular diseases and gene therapies
Classe 44
Medical services; medical servicesnamely medical diagnosis through molecular biologygenetic engineering and biotechnology methodsin particular in the field of eye diseases; therapy servicesin particular gene therapy for medical treatment purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
24 publicações encontradas
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/06/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/06/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
31/05/2026
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
06/04/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/03/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/03/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/01/2026
PUBO
PUBLISHED FOR OPPOSITION
13/01/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/01/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/12/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/12/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/12/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/12/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
26/09/2025
RFNT
REFUSAL PROCESSED BY IB
12/07/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/06/2025
RFRR
REFUSAL PROCESSED BY MPU
20/06/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
17/04/2025
CNRT
NON-FINAL ACTION WRITTEN
16/04/2025
DOCK
ASSIGNED TO EXAMINER
09/04/2025
MAFR
APPLICATION FILING RECEIPT MAILED
03/01/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/01/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/01/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RHYGAZE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.